UniProt Q9UBE8 · PDB · AlphaFold · Substrate: MBP · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Dasatinib | 75.1% | 24.9% | 87.97 | 0.699 |
| 2 | Darovasertib | 72.6% | 27.4% | 96.99 | 0.719 |
| 3 | Encorafenib | 71.3% | 28.6% | 98.50 | 0.755 |
| 4 | Pemigatinib | 51.3% | 48.7% | 98.23 | 0.718 |
| 5 | Bosutinib | 45.9% | 54.1% | 87.22 | 0.555 |
| 6 | Ripretinib | 44.4% | 55.6% | 92.95 | 0.674 |
| 7 | Dabrafenib | 33.3% | 66.7% | 94.74 | 0.633 |
| 8 | Pazopanib | 32.3% | 67.7% | 97.49 | 0.672 |
| 9 | Zanubrutinib | 30.0% | 70.0% | 98.24 | 0.788 |
| 10 | Tivozanib | 25.0% | 75.0% | 92.42 | 0.673 |
| 11 | Ceritinib | 17.2% | 82.8% | 95.44 | 0.618 |
| 12 | Ponatinib | 16.8% | 83.2% | 78.23 | 0.534 |
| 13 | Gefitinib | 15.3% | 84.7% | 99.25 | 0.650 |
| 14 | Lenvatinib | 10.7% | 89.3% | 97.74 | 0.726 |
| 15 | Dacomitinib | 10.6% | 89.4% | 97.99 | 0.664 |
| 16 | Tucatinib | 10.4% | 89.6% | 99.75 | 0.652 |
| 17 | Selpercatinib | 10.2% | 89.8% | 96.72 | 0.635 |
| 18 | Alpelisib | 10.0% | 90.0% | 97.22 | 0.720 |
| 19 | Afatinib | 9.8% | 90.2% | 98.50 | 0.709 |
| 20 | Repotrectinib | 9.2% | 90.8% | 84.21 | 0.608 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.23
- Epithelial log2(TPM+1): 3.32
- Fold change: -0.09
- Status: No significant change
Selectivity landscape vs inhibition on NLK
Each point is one of the 92 approved drugs; color = inhibition % on NLK.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…